866-997-4948(US-Canada Toll Free)

Q Fever - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 36 Pages

Q Fever - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2017, provides an overview of the Q Fever (Infectious Disease) pipeline landscape.

Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscle pain. Risk factors include occupations. Treatment includes antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Q Fever - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Q Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Q Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Q Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Q Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Q Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Q Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Q Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Q Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Q Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Q Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Q Fever - Overview 5
Q Fever - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Pipeline by Universities/Institutes 8
Products under Development by Companies 9
Products under Development by Universities/Institutes 10
Q Fever - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Q Fever - Companies Involved in Therapeutics Development 18
Aradigm Corp 18
Grifols SA 18
Q Fever - Drug Profiles 19
ARD-3100 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
ARD-3150 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
ciprofloxacin hydrochloride - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
q fever vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Q Fever - Dormant Projects 33
Q Fever - Product Development Milestones 34
Featured News & Press Releases 34
Sep 20, 2012: UK Scientists Report Successful Testing Of Aradigms Inhaled Liposomal Ciprofloxacin In Q Fever 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
Number of Products under Development for Q Fever, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products under Development by Universities/Institutes, H2 2017 8
Products under Development by Companies, H2 2017 9
Products under Development by Universities/Institutes, H2 2017 10
Number of Products by Stage and Target, H2 2017 12
Number of Products by Stage and Mechanism of Action, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Q Fever - Pipeline by Aradigm Corp, H2 2017 18
Q Fever - Pipeline by Grifols SA, H2 2017 18
Q Fever - Dormant Projects, H2 2017 33

List of Figures
Number of Products by Targets, H2 2017 11
Number of Products by Stage and Targets, H2 2017 11
Number of Products by Mechanism of Actions, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *